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Abstract
Background: Because strict glucose control is important for reducing the complications of diabetes, the self-
monitoring of blood glucose is one of the fundamental treatment modalities. Many glucometers have been de-
veloped. In the present study, we evaluated a new glucometer: GlucoDr Plus (Allmedicus, Anyang, Gyeonggi-do,
Republic of Korea).
Methods: The evaluation was performed based on Clinical and Laboratory Standards Institute guidelines.
Interferences by ascorbic acid, uric acid, maltose, and acetaminophen were examined, and the performance of
the unit was compared to those of six other glucometers. The effects of hematocrit, of oxygen partial pressure
(PaO2), and of multiple users were also evaluated.
Results: Within-run, between-run, between-day, and total imprecision (coefficients of variation) were 0.99–
4.98%. Satisfactory linearity was found for glucose concentrations of 32.5–786.5 mg=dL (R2¼ 0.9985). A com-
parison with the reference laboratory method showed close concordance over the entire range of concentrations
evaluated (R2¼ 0.9869). No significant effects were noted due to added interferents, hematocrit, and PaO2.
Conclusions: The GlucoDr Plus showed acceptable performance in terms of precision and linearity. It was
minimally affected by various interferents. GlucoDr Plus is suitable for the self-monitoring of blood glucose by
patients with diabetes.
Introduction
Diabetes mellitus is a metabolic disease that developsbecause of derangement of an individual’s capacity to
control blood glucose. In 2000, the number of patients with
diabetes worldwide was estimated to be approximately 171
million, and this figure is expected to increase to 366 million in
2030.1 The discovery that strict blood glucose control is more
helpful than relieving the symptoms of diabetes in terms
of preventing complications represented a sentinel point in
the treatment of diabetes.2,3 To achieve a good blood glucose
control, patients should constantly check their blood glucose
levels, and thus a portable glucometer is an essential device.
There are two types of glucometers, which rely on different
signal detection principles, i.e., spectroscopic and electroche-
mical meters. When using spectroscopic meters, the amount of
blood sample introduced to the response layer depends on
the amount of blood loaded, which leads to measurement
errors, and thus electrochemical meters are more widely used
today. Methods of measuring blood glucose are classified ac-
cording to the enzyme and coenzyme used, for example, the
glucose oxidase method, the glucose dehydrogenase-based
NAD method, the glucose dehydrogenase-based pyrroloqui-
noline quinine method, the glucose dehydrogenase-based
flavin adenine dinucleotide (FAD) method, the glucose hexo-
kinase method, and others. Of these, the glucose oxidase
method is most widely used. However, this method requires
oxygen to convert glucose into gluconolactone, which can re-
sult in spuriously elevated values when oxygen contents are
high in capillary or arterial blood.4 This problem can be over-
come by using glucose dehydrogenase, which is not affected
by oxygen content. However, the glucose dehydrogenase-
based pyrroloquinoline quinine method is subject to interfer-
ence by sugars other than glucose.5
In the present study, we evaluated the performance of a new
glucometer, GlucoDr Plus (Allmedicus, Anyang, Gyeonggi-
do, Republic of Korea), which utilizes a glucose dehydrogenase-
based FAD method. We compared its performance with those
of widely used glucometers.
Materials and Methods
Glucometer
The GlucoDr Plus is an electrochemical glucometer based
on the glucose dehydrogenase method and displays blood
glucose levels based on electric current generated by a
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reaction between an enzyme immobilized on an electrode and
glucose in blood. The system uses FAD–glucose dehydroge-
nase, which minimizes the effects of oxygen as well as sugars
other than glucose. Gold is used for electrodes because of its
noble nature and its high conductivity.
Precision
Three control solutions and five venous EDTA-treated
whole blood samples were used to evaluate precision. Control
solutions were measured twice a day for 20 days, as re-
commended by the Clinical Laboratory Standards Institute
(CLSI), and within-run, between-run, between-day, and total
imprecisions were calculated.6 Within-run imprecision in
patient samples was assessed using 12 consecutive measure-
ments of venous whole blood samples at five different
concentrations.
Linearity
Two venous whole blood samples with glucose concen-
trations of 32.5 and 786.5 mg=dL were used, as recommended
by the CLSI.7 The two samples were mixed in volume ratios of
4:0, 3:1, 2:2, 1:3, and 0:4 to produce five samples with different
concentrations. Each sample was measured four times.
Effect of hematocrit
Twenty-one whole venous blood EDTA samples with he-
matocrit values of 12.1–58.0% were selected and measured
with GlucoDr Plus. For each sample, plasma glucose con-
centrations were measured using an automated chemistry
analyzer (model 200FR, Toshiba, Tokyo, Japan), and hemat-
ocrit effects were evaluated by calculating the ratio of glucose
values measured by the glucometer and the automated chem-
istry analyzer.
Interference
Two venous whole blood EDTA-treated samples with dif-
ferent glucose concentrations were selected and measured
five times with GlucoDr Plus to determine glucose concen-
trations before adding interferents. Low and high concentra-
tions of ascorbic acid (3.5 and 6 mg=dL), acetaminophen
(3 and 8 mg=dL), uric acid (7 and 25 mg=dL), and maltose
(10 and 200 mg=dL) were then mixed with samples, and
glucose concentrations were measured. The glucose concen-
trations determined before and after adding the interferents
were compared.8
Comparison with other glucometers
and the automated chemistry analyzer
One hundred twenty venous whole blood EDTA-treated
samples with glucose concentrations in the range 33–
327 mg=dL were randomly selected and tested using GlucoDr
Plus and six other glucometers: Accu-Chek (Roche Korea,
Seoul, Republic of Korea), OneTouch Ultra (LifeScan
Korea, Seoul), Optium Xceed (Abbott Korea, Seoul), Mi-
rae 3.3G (Infopia, Anyang), Gluchec (KMH, Anyang), and
MWD Pen Sensor (MedWatchDoc Gmbh & Co., Lüneburg,
Germany). All tests were performed twice, and results were
evaluated according to the CLSI guidelines.9
Test strip stability
Three control solutions were measured using GlucoDr Plus
immediately and 1, 3, and 7 days after opening the test strip
container. All tests were performed three times, and average
values were compared.
Effect of multiple users
Three inexperienced persons were trained to operate
GlucoDr Plus just prior to testing. Each person measured
three control samples independently.
Effect of oxygen partial pressure (PaO2)
One hundred arterial whole blood heparinized samples
with PaO2 values of 51.6–189.4 mm Hg were randomly se-
lected. Each sample was measured twice using GlucoDr Plus.
Their plasma glucose concentrations were also measured
twice using an automated chemistry analyzer. The effect of
PaO2 was evaluated by calculating the ratio of glucose val-
ues measured by the automated chemistry analyzer and the
glucometer.
Statistics
All statistical analyses were performed using Excel 2003
(Microsoft Corp., Redmond, WA) and SPSS version 15.0 for
Windows (SPSS Inc., Chicago, IL). A correlation equation and
Pearson’s correlation coefficient (R2) were obtained during the
correlation analysis. Clarke error grid analysis was performed
to evaluate the clinical performance of the glucometer. Values
of P< 0.05 were deemed significant.
Results
Precision
Coefficients of variation (CVs) of within-run, between-
runs, between-days, and total imprecisions using the control
solutions were 1.5–2.2%, 1.7–3.9%, 1.0–2.3%, and 2.6–5.0%,
respectively (Table 1). CVs of with-run imprecisions using
venous whole blood samples for glucose concentrations
ranged from 1.3% to 5.0% (Table 1). GlucoDr Plus showed an
acceptable range of imprecision that nearly meets the re-
quirements for glucose measurements.10,11
Linearity
GlucoDr Plus showed acceptable linearity in the range
32.5–786.5 mg=dL (Fig. 1). The coefficient of determination
was 0.998, and the slope and intercept were 1 and 0, respec-
tively.
Effect of hematocrit
To evaluate the effect of hematocrit, 21 samples with a
hematocrit of 12.1–58.0% and glucose concentrations in the
range 57.5–369.5 mg=dL were used. Most of the values mea-
sured by GlucoDr Plus were slightly lower than those from
the Toshiba 200-FR with minor exceptions. Glucose values
obtained using GlucoDr Plus were different by 10.9 mg=dL
and 7.1% on average. However, as shown in Figure 2, glu-
cose values measured with GlucoDr Plus were not signifi-
cantly affected by hematocrit (R2¼ 0.0437, P¼ 0.965).
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Interference
Table 2 shows changes in measured glucose values after
adding low or high concentrations of ascorbic acid, uric acid,
maltose, or acetaminophen. No significant interference was
observed from the four interferents tested. A degree of posi-
tive interference was found for ascorbic acid, up to about 10%
of the initial glucose concentration. Interferences caused by
uric acid, maltose, and acetaminophen at the difference glu-
cose concentration were negligible.
Comparison with the automated chemistry analyzer
Correlations between the automated chemistry analyzer
and the GlucoDr Plus and the six glucometers are shown in
Table 3. All seven glucometers showed acceptable correla-
tions (R2¼ 0.9643–0.993). In terms of Clarke error grid anal-
ysis, all values were distributed in zone A (Fig. 3).
Test strip stability
Test strips were stable for 7 days after exposed to ambient
environment. The average difference between glucose values
after 7 days was within 3.4% of values obtained immedi-
ately after opening (Fig. 4). The differences at low and high
concentrations were statistically significant (P< 0.01) but
clinically insignificant (44.8–48.2 mg=dL at low concentration
and 400.8–410.0 mg=dL at high concentration). The difference
at the middle concentration was statistically and clinically
insignificant (P¼ 0.271, 127.6–132.2 mg=dL).
Effect of multiple users
The CVs of glucose values measured by individual users
were 4.7–6.3%, 1.7–2.9%, and 2.5–2.8% for low, middle, and
high concentration control solutions. Average values measured
by the three users differed significantly at low concentration
Table 1. Imprecision of GlucoDr Plus
At mean glucose concentration (mg=dL)
Level 1 (44.3) Level 2 (128.1) Level 3 (365.6)
Control solutions
Within-run imprecision (%) 1.5 2.0 2.2
Between-run imprecision (%) 1.7 3.9 3.2
Between-day imprecision (%) 1.0 2.3 1.0
Within-device imprecision (%) 2.6 5.0 4.1
Level 1 (33.4) Level 2 (95.8) Level 3 (136.4) Level 4 (204.9) Level 5 (289.4)
Patient samples
Within-run imprecision (%) 5.0 1.3 2.7 3.0 2.1
Imprecision (%) is defined as CV.
FIG. 1. Linearity of GlucoDr Plus measurements. The
x-axis represents the expected value of glucose concentra-
tions, and the y-axis represents measured values generated
by the glucometer.
FIG. 2. Effect of hematocrit. The ratio was calculated as the
glucose level resulted from the GlucoDr Plus divided by
the glucose level measured by the Toshiba 200-FR analyzer.
The dotted line indicates a reference line, i.e., a ratio of 1. No
significant correlation was noted between the hematocrit and
the ratio calculated.
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(P¼ 0.03) but not at the middle (P¼ 0.066) or high concentra-
tions (P¼ 0.599). One user generated slightly lower values
compared to those from others with a small difference (up to
7.7 mg=dL).
Effect of PaO2
Figure 5 shows the results of arterial blood samples with
PaO2 values ranging from 51.6 to 189.4 mm Hg. Measured
glucose values in arterial whole blood and plasma were not
affected by PaO2 (R
2¼ 0.0302, P¼ 0.086).
Discussion
Most patients with diabetes depend on a glucometer for
their blood glucose control. Glucometer readings are used to
guide patients to adjust insulin dosages in type 1 diabetes, and
many type 2 diabetes patients are also using a glucometer
to monitor their blood glucose levels.12 Thus, the analytical
performance of the glucometer is of considerable importance
as severe inaccuracies, imprecisions, or interferences may lead
to inadequate treatment and adverse reactions. There is no
guideline that specifies the quality goals only for precision.
Most guidelines recommend total analytical goals, such as 5%
from the American Diabetes Association13 or 10% from the
Clinical Laboratory Improvement Amendment 88 goal. None
of currently used glucometers meet the above criteria. In this
study, GlucoDr Plus was found to have a precision that was
similar to or better than that of the other commercially avail-
able glucometers tested. Precision using patient samples was
also excellent, although the CV was a little higher at low con-
centrations, which was expected. The International Standard
Organization also recognizes this and thus recommends that
the imprecision results should be reported in terms of CVs at
glucose concentrations >75 mg=dL and that SDs should be
reported at concentrations <75 mg=dL.11 In terms of linearity,
GlucoDr Plus showed excellent linearity in the range of 32.5–
786.5 mg=dL. The majority of commonly used glucometers do
not guarantee linearity at>500 or 600 mg=dL or<40 mg=dL.4,14
This wider linear range of GlucoDr Plus may give some ad-
ditional use for patients with extremely low or high levels of
glucose that require immediate medical attention. The in-
strument may also be useful for neonates, who frequently
have exceptionally low glucose levels,15 and for those patients
suffering from brittle diabetes with uncontrollable glucose
levels. However, further validation with samples from pa-
tients with various clinical conditions, such as dehydration,
hemoconcentration, acidosis, or hypoglycemia, is required. In
terms of correlations with automated chemistry analyzer
findings, the results of all glucometers were comparable.
Because the red blood cell has less water than plasma, the
amount of water may change in whole blood depending on











3.5 80.6 þ0.4 þ0.5
3.5 134.6 þ13.6 þ10.1
6 71.4 þ3.6 þ5.0
6 118.2 þ1.6 þ1.4
Uric acid
7 80.6 5.0 6.2
7 134.6 þ7.2 þ5.3
25 80.6 1.0 1.2
25 134.6 þ8.2 þ6.1
Maltose
10 80.6 8.0 9.9
10 134.6 1.4 1.0
200 71.4 þ1.4 þ2.0
200 118.2 5.8 4.9
Acetaminophen
3 80.6 1.8 2.2
3 134.6 4.0 3.0
8 71.4 þ1.6 þ2.2
8 118.2 þ0.2 þ0.2
aThe concentrations of each interferent material added.
bGlucose concentration of sample to which each interferent mate-
rial was mixed.
cThe difference of glucose concentration measured after addition of
interferent substances. This was calculated by subtracting the mea-
sured value after the addition from the value before the manipulation.
Data are absolute glucose levels and the relative percentage compared
to initial values. A negative value means that addition of interferent
substances lowered the measured values.




(mg=dL)a Slope (95% CI)b Intercept (95% CI)b Mean bias (mg=dL)c
Correlation
coefficientd
GlucoDr Plus 29–309 0.963 (0.942–0.983) 5.772 (7.845 to 3.700) 9.1 (10.2 to 8.1) 0.993
Accu-Chek 28–312 0.924 (0.910–0.938) 3.447 (4.895 to 2.000) 10.2 (11.2 to 9.3) 0.996
OneTouch Ultra 30–309 0.965 (0.936–0.994) 5.660 (8.618 to 2.703) 8.8 (10.3 to 7.3) 0.987
Optium Xceed 20–321 1.042 (1.019–1.066) 13.735 (16.172 to 11.299) 9.9 (11.2 to 8.7) 0.992
Mi-rae 3.3G 17–330 0.998 (0.965–1.031) 17.649 (21.038 to 14.260) 17.8 (19.5 to 16.2) 0.984
Gluchec 30–320 0.867 (0.836–0.897) 9.198 (6.085–12.312) 2.7 (4.7 to 0.8) 0.964
MWD Pen Sensor 24–235 0.988 (0.964 –1.013) 1.220 (2.978–0.538) 2.0 (2.8 to 1.2) 0.991
aRange of glucose levels measured using each glucometer.
bSlope and intercept of regression analysis between each glucometer and the Toshiba 200-FR. Ninety-five percent confidence intervals of
each value are given in parentheses.
cDifference between the glucose levels on the glucometer and the Toshiba 200-FR. A negative value means that the glucometer generated
lower values of glucose compared to those resulting from the Toshiba 200-FR. Ninety-five percent confidence intervals of each value are
presented in parentheses.
dPearson’s correlation coefficient between the glucose levels on the glucometer and the Toshiba 200-FR.
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the hematocrit. Therefore, it is known that blood glucose
is measured lower than its true concentration because the
amount of water becomes similar to that of plasma as the
hematocrit gets higher.16 Compared to the automated chem-
istry analyzer, GlucoDr Plus appeared to produce slightly
lower values as hematocrit levels increased, although this was
not significant. The interference caused by various substances
is one of the mostly easily overlooked problems associated
with glucometer use. Ascorbic acid is the most well-known
interferent, and high levels of ascorbic acid may cause positive
or negative divergences.13 In the present study, ascorbic acid,
uric acid, maltose, and acetaminophen caused less than 11%
differences in glucose levels. Higher level of interferents
would have probably caused more severe interference, but
higher levels were considered clinically unnecessary. GlucoDr
Plus uses FAD extracted from Aspergillus oryzae as the cofac-
tor, and it has been shown that the FAD–glucose dehydro-
genase system is insensitive to oxygen and has high substrate
specificity.17 Furthermore, PaO2 had no significant effects on
FIG. 3. Clarke error grid analysis of GlucoDr Plus measurements. The x-axis displays the glucose level recorded by the
Toshiba 200-FR analyzer, and the glucose level generated from the GlucoDr Plus is displayed on the y-axis. All the measured
valued are in zone A, i.e., acceptable error range.
FIG. 4. Strip stability of GlucoDr Plus measurements. The
day after opening is given on the x-axis. Measured values are
glucose levels measured by the GlucoDr Plus expressed as
means 2 SEs.
FIG. 5. Effect of PaO2. The ratio was calculated as the glu-
cose level measured by the GlucoDr Plus divided by the
glucose level measured by the Toshiba 200-FR analyzer. The
dotted line indicates a reference line, i.e., a ratio of 1. No sig-
nificant correlation was noted between the PaO2 and the ratio
calculated.
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GlucoDr Plus, and test strip stability was maintained for a
week. The effects of longer test strip exposure periods and
other environmental factors, such as temperature and hu-
midity, should be determined by further study.
We evaluated the performance of GlucoDr Plus, a new
FAD–glucose dehydrogenase-based electrochemical gluco-
meter, using a standardized protocol. GlucoDr Plus matched
or bettered the performances of other commonly used de-
vices. We suggest that GlucoDr Plus is suitable for the self-
monitoring of blood glucose in patients with diabetes.
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